Get Premium
EN
EnglishРусскийDeutschFrançaisEspañolPortuguêsItalianoNederlandsPolskiTürkçeالعربية日本語한국어中文УкраїнськаአማርኛБългарскиČeštinaΕλληνικάفارسیSuomiFilipinoGàidhligעבריתHaitian CreoleMagyarՀայերենIndonesiaខ្មែរಕನ್ನಡМакедонскиMelayuNorsk bokmålOromooਪੰਜਾਬੀRomânăSlovenčinaSlovenščinaСрпскиSvenskaไทยTiếng Việt中文 (繁體)
Start free
☰
Markets
Daily briefMacroAttention radarAI forecastsNews
Ideas
Ideas of the monthThemesModel portfoliosLive recordWeekly digestsLearnGlossary
ScreenerDividends
Dividend calendarDividend calculatorFinancial independence
My portfolioGoals
Blog Invest new Get Premium Recommended Tools Invite Friends My account
Instrument overview

URGNUroGen Pharma Ltd.

StockNasdaqIsraelHealth careEU retail: available

−0.5% today · +67.2% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 19% of the instruments we score

Trend: among the best of its peers; priced higher than most peers. No dividend.

+ Add to my portfolioCompare with peers

UroGen Pharma Ltd. (URGN) belongs to the Health care sector and is listed on Nasdaq; country: Israel. Its market value is about €1.5B. Over the past 12 months the price changed by +67.2%, with an annualised volatility of 62% and a largest fall of 42%. Hard red flags in our rules-based screen: Financial distress.

Smart Score

How it is scored →
Balanced 1/101/10Balanced
Weights for long-horizon accumulation: more quality and trend, no dividend requirement. These are three ways to weigh the same factors, not three properties of the instrument; Income compares within the sector, so a low yield can still score high. More in the glossary →1/10
Default weights: value, quality, trend, stability and dividend safety together. These are three ways to weigh the same factors, not three properties of the instrument; Income compares within the sector, so a low yield can still score high. More in the glossary →1/10
Weights for income: dividend safety counts most; shown for dividend payers only. These are three ways to weigh the same factors, not three properties of the instrument; Income compares within the sector, so a low yield can still score high. More in the glossary →—/10

The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.

Compared with: all companies in Asia-Pacific (n = 61)

Current rating first published: · last recomputed · rating log

Factor scores

How cheap the company is versus peers: earnings, cash flow, book value and sales relative to its price. More in the glossary →better than 2% of peers
Profitability, balance-sheet safety, growth and capital discipline versus peers. More in the glossary →better than 28% of peers
Price trend over the last 12 and 6 months (excluding the last month) and distance from the 52-week high. More in the glossary →better than 84% of peers
Lower price swings, lower market sensitivity (beta) and shallower drawdowns score higher. More in the glossary →better than 27% of peers

Percentiles within the peer group (100 = the best of its peers); dividend safety in points.

Main drivers

  • Gross profit growth / assets (5 y)supports the score · better than 84% of peers
  • 12-month trend (ex last month)supports the score · better than 88% of peers
  • Accrualsweighs on the score · better than 1% of peers

Red flags and notes

  • Serious warning. Altman Z in the distress zone and negative free cash flow. More in the glossary → Altman Z in the distress zone and negative free cash flow.
  • Caution. Negative free cash flow in at least two of the last three years. More in the glossary → Negative free cash flow in at least two of the last three years.
  • Caution. Accruals or the Beneish M-score are in the watch zone. More in the glossary → Accruals or the Beneish M-score are in the watch zone.
  • Caution. Book equity is below zero. More in the glossary → Book equity is below zero.

Price chart

Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.

URGN · chart by TradingView

Key metrics

Valuation

P/S
8.7
Free-cash-flow yield
−9.6%
Market cap (EUR)
€1.5B

Profitability and debt

Gross margin
90.8%

Dividends

Dividend yield
0.00%
Years of dividend growth
0

Returns and risk

1 day
−0.5%
1 month
−17.5%
1 year
+67.2%
Volatility, 1 yr
61.8%
Max drawdown, 1 yr
−42.2%
Beta
1.10

Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.

Similar companies

Same sector and region, closest in market value.
NVCRNovoCure Limited1/100.0%6.0%
CMPSCOMPASS Pathways Plc American Depository Shares1/100.0%87.5%
QUREuniQure N.V.1/100.0%−64.3%
ALVOAlvotech1/100.0%−37.2%
DMRADamora Therapeutics Inc.—/100.0%201.8%
ESTAEstablishment Labs Holdings Inc.1/100.0%31.5%
GHRSGH Research PLC1/100.0%47.9%
PHVSPharvaris N.V.2/100.0%44.9%

News and filings

What the marks mean
  • FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
  • Media reportA headline from a named media outlet. We link to it and do not check it.
  • RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.

Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.

Score changes in the last 12 months

Every published rating and change, logged when it was published (EU Market Abuse Regulation).

Show the log: 1 entry
DateEventBalancedGrowth · IncomeWarningsPrice at publication
First rating 1/10 1 · — Available with Invest Pro

Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.